by Jing Zhou, Tianjiao Lan, Hao Lu, Jay Pan Background While China has implemented reimbursement-linked drug price negotiation annually since 2017, emphasizing value-based pricing to achieve a value-based strategic purchase of medical insurance, whether drug prices became better aligned with clinical value after price negotiation has not been sufficiently established. This study aimed to assess […]
*Manufacturers of 10 Drugs Slated for Medicare Price Negotiation Spent Billions More on Buybacks, Dividends and Executive Compensation than R&D.* US drug companies have worked hard to corrupt the system of studies to measure the effects of approved and proposed medicines. They can do this because the investigations get their funds from the drug companies. […]